



10:00 - 10:30 e-Poster Discussion Session 04 Station 04
Moderation: Steve Morris, United States of America

- 10:00 - 10:05 **PD013a - ASSOCIATION OF PRECONCEPTION BODY MASS INDEX AND GESTATIONAL WEIGHT GAIN WITH ADVERSE OUTCOMES IN PREGNANT PEOPLE WITH DIABETES**
Chiara Fabris, (Center for Diabetes Technology, , United States of America)
- 10:05 - 10:10 **PD014 - DURABLE GLYCEMIC CONTROL WITH BMF-219 DURING OFF-TREATMENT PERIOD AT WEEK 26: A PHASE 1/2 TRIAL OF BMF-219 IN PATIENTS WITH TYPE 2 DIABETES (COVALENT-111)**
Steve Morris, (Biomea Fusion, , United States of America)
- 10:10 - 10:15 **PD015 - SOTAGLIFLOZIN, A DUAL SGLT1 AND SGLT2 INHIBITOR, IN PATIENTS WITH TYPE 1 DIABETES AND CHRONIC KIDNEY DISEASE: A POST HOC ANALYSIS OF INTANDEM3 STUDY**
Michael Davies, (Lexicon Pharmaceuticals, , United States of America)
- 10:15 - 10:20 **PD016 - THE EFFECT OF ADDITIONAL TREATMENT WITH EMPAGLIFLOZIN OR SEMAGLUTIDE ON ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS IN SUBJECTS WITH TYPE 1 DIABETES MELLITUS - ENDIS STUDY**
Maja Navodnik, (General Hospital Celje, , Slovenia)